Please login to the form below

Not currently logged in
Email:
Password:

Triumeq

This page shows the latest Triumeq news and features for those working in and with pharma, biotech and healthcare.

Gilead says switching studies back new HIV therapy Biktarvy

Gilead says switching studies back new HIV therapy Biktarvy

Gilead says switching studies back new HIV therapy Biktarvy. Patients who switched from rival Triumeq could maintain viral suppression over the trial period. ... Both Biktarvy and Triumeq are fixed-dose triple therapies for HIV delivered once-daily, and

Latest news

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    which was first approved in the US in 2013 and is a key component of ViiV’s latest HIV product launches including three-drug combo Triumeq and recently-approved Juluca. ... forecasts. Tivicay and Triumeq posted strong growth to reach £1.4bn and

  • GSK’s ViiV gets US okay for two-drug HIV regimen GSK’s ViiV gets US okay for two-drug HIV regimen

    ViiV has said Juluca will be priced at about $31, 000-a-year, comparable to its three-drug HIV regimen Triumeq (abacavir, lamivudine and dolutegravir), a $1.7bn product that is

  • CDC backs GSK’s Shingrix over Merck & Co’s Zostavax CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

    Once again HIV therapies Tivicay (dolutegravir) and Triumeq (dolutegravir, abacavir and lamivudine) - up 45% to £1.47bn - led the advance amongst GSK’s prescription pharma business, with support from new asthma

  • ViiV files two-drug HIV maintenance regimen ViiV files two-drug HIV maintenance regimen

    s fast-growing Triumeq (dolutegravir, abacavir and lamivudine) but not - as it had hoped - a superior profile. ... With Triumeq likely to feel the pinch ViiV will be hoping its emphasis on two-drug regimens could keep it on a competitive footing.

  • Gilead plans fightback against HIV arch-rival ViiV Gilead plans fightback against HIV arch-rival ViiV

    Triumeq, which contains rival integrase Tivicay (dolutegravir) as well as abacavir and lamivudine. ... and Triumeq, which grew more than 80% to reach £2.7bn ($3.5bn) in sales last year.

More from news
Approximately 5 fully matching, plus 17 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics